{"altmetric_id":2996219,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":4,"unique_users":["100000445602493","100001970301308","579254068","1653562713"],"posts_count":5},"googleplus":{"unique_users_count":1,"unique_users":["Consultorio de Alergia e Inmunolog\u00eda - Dr. Juan Carlos Ivancevich"],"posts_count":1},"news":{"unique_users_count":1,"unique_users":["suddeutsche_de"],"posts_count":1},"total":{"posts_count":18},"twitter":{"unique_users_count":10,"unique_users":["EmmaPettengale","Aller_MD","alergologos","SocLatAlergia","Interasma","s_inma","AsthmaTuz","asthma_papers","jvalverde64","Allergy"],"posts_count":11}},"selected_quotes":["Omalizumab para asm\u00e1ticos con pobre adherencia a terapia con corticoides inhalados (abstract en ingl\u00e9s v\u00eda","Omalizumab may be an alternative for asthma patients with poor adherence to inhaled corticosteroid therapy"],"citation":{"abstract":"Omalizumab, an anti-IgE monoclonal antibody, is administered by injection once or twice monthly in offices and clinics. It offers a potential alternative intervention for patients with allergic asthma that is not well controlled because of recalcitrant poor adherence to inhaled corticosteroid therapy.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e63cf058f610005723","authors":["Hendeles L","Khan YR","Shuster JJ","Chesrown SE","Abu-Hasan M"],"doi":"10.1016\/j.anai.2014.10.012","first_seen_on":"2014-12-18T16:01:16+00:00","funders":["niehs"],"issns":["1081-1206","1534-4436"],"issue":"1","journal":"Annals of Allergy, Asthma & Immunology","last_mentioned_on":1429283047,"links":["https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=8&redirect=http%3A%2F%2Fwww.annallergy.org%2Farticle%2FS1081-1206%252814%252900748-0%2Fabstract%3Frss%3Dyes&code=anai-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=9&redirect=http%3A%2F%2Fwww.annallergy.org%2Farticle%2FS1081-1206%252814%252900748-0%2Fabstract%3Frss%3Dyes&code=anai-site","http:\/\/www.annallergy.org\/article\/S1081-1206(14)00748-0\/abstract?rss=yes&utm_content=buffer927aa&utm_medium=social&utm_source=plus.google.com&utm_campaign=buffer","http:\/\/www.annallergy.org\/article\/S1081-1206(14)00748-0\/abstract?rss=yes&utm_content=buffer927aa&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer&fb_ref=Default&fb_source=group","http:\/\/www.annallergy.org\/article\/S1081-1206(14)00748-0\/abstract?rss=yes&utm_content=buffer927aa&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25528738?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/www.annallergy.org\/article\/S1081-1206(14)00748-0\/abstract"],"pdf_url":"http:\/\/www.annallergy.org\/article\/S1081120614007480\/pdf","pmid":"25528738","pubdate":"2015-01-01T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Immunology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"58","subjects":["pulmonarymedicine","allergyandimmunology"],"title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy","type":"article","volume":"114","mendeley_url":"http:\/\/www.mendeley.com\/research\/omalizumab-therapy-asthma-patients-poor-adherence-inhaled-corticosteroid-therapy-2"},"altmetric_score":{"score":16.1,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":16.1},"context_for_score":{"all":{"total_number_of_other_articles":5005300,"mean":5.928903969976,"rank":289697,"this_scored_higher_than_pct":94,"this_scored_higher_than":4715065,"rank_type":"exact","sample_size":5005300,"percentile":94},"similar_age_3m":{"total_number_of_other_articles":175265,"mean":8.1416655673728,"rank":14162,"this_scored_higher_than_pct":91,"this_scored_higher_than":161079,"rank_type":"exact","sample_size":175265,"percentile":91},"this_journal":{"total_number_of_other_articles":1245,"mean":5.908615755627,"rank":81,"this_scored_higher_than_pct":93,"this_scored_higher_than":1164,"rank_type":"exact","sample_size":1245,"percentile":93},"similar_age_this_journal_3m":{"total_number_of_other_articles":68,"mean":5.2361791044776,"rank":3,"this_scored_higher_than_pct":95,"this_scored_higher_than":65,"rank_type":"exact","sample_size":68,"percentile":95}}},"demographics":{"poster_types":{"member_of_the_public":6,"researcher":2,"practitioner":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":1,"Scientists":2,"Members of the public":6,"Practitioners (doctors, other healthcare professionals)":1}},"mendeley":{"by_status":{"Researcher":1,"Student  > Master":1,"Other":2,"Student  > Bachelor":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":2,"Agricultural and Biological Sciences":2,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"GB":1,"AR":1,"ES":1,"US":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/EmmaPettengale\/status\/545678953231699968","license":"datasift","rt":["Aller_MD"],"citation_ids":[2996219],"posted_on":"2014-12-18T20:36:15+00:00","author":{"name":"Emma Pettengale","image":"https:\/\/pbs.twimg.com\/profile_images\/460690851719413760\/Vh_lCPWE_normal.jpeg","description":"Commissioning Editor for @PPPublishing All views expressed are my own, RT\u2260Endorsement","id_on_source":"EmmaPettengale","tweeter_id":"390046155","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":840},"tweet_id":"545678953231699968"},{"url":"https:\/\/twitter.com\/Aller_MD\/status\/545609552247676928","license":"datasift","citation_ids":[2996219],"posted_on":"2014-12-18T16:00:28+00:00","author":{"name":"Juan C Ivancevich MD","url":"http:\/\/www.ivancevichmd.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/906525202787520514\/NdEfNrQI_normal.jpg","description":"Allergist - Twittering on #allergy, #asthma & #immunology. Associate Professor of Immunology, del Salvador University, WAO website Chief Editor","id_on_source":"Aller_MD","tweeter_id":"23184067","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":5438},"tweet_id":"545609552247676928"},{"url":"https:\/\/twitter.com\/alergologos\/status\/545612036752035840","license":"datasift","citation_ids":[2996219],"posted_on":"2014-12-18T16:10:21+00:00","author":{"name":"Alergiayasma","url":"http:\/\/www.alergiayasma.es","image":"https:\/\/pbs.twimg.com\/profile_images\/439087675291611136\/-vfBAAzB_normal.jpeg","description":"Alergia y Asma Andaluc\u00eda","id_on_source":"alergologos","tweeter_id":"2222214355","geo":{"lt":null,"ln":null},"followers":1571},"tweet_id":"545612036752035840"},{"url":"https:\/\/twitter.com\/SocLatAlergia\/status\/545612510456725504","license":"datasift","rt":["Aller_MD"],"citation_ids":[2996219],"posted_on":"2014-12-18T16:12:14+00:00","author":{"name":"SLaai","url":"http:\/\/www.slaai.org","image":"https:\/\/pbs.twimg.com\/profile_images\/469173940116393986\/4DtHZNic_normal.png","description":"Sociedad Latinoamericana de Alergia, Asma e Inmunolog\u00eda","id_on_source":"SocLatAlergia","tweeter_id":"367878837","geo":{"lt":null,"ln":null},"followers":1255},"tweet_id":"545612510456725504"},{"url":"https:\/\/twitter.com\/Interasma\/status\/545612616224501760","license":"datasift","citation_ids":[2996219],"posted_on":"2014-12-18T16:12:39+00:00","author":{"name":"Interasma","url":"http:\/\/www.interasma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/481070665450016770\/o6EbOA8x_normal.jpeg","description":"Interasma is an international health organization focused on all aspects of asthma which bridges the gap between academia and the world of clinical practice.","id_on_source":"Interasma","tweeter_id":"147594153","geo":{"lt":null,"ln":null},"followers":1586},"tweet_id":"545612616224501760"},{"url":"https:\/\/twitter.com\/s_inma\/status\/545616254808387584","license":"datasift","rt":["alergologos"],"citation_ids":[2996219],"posted_on":"2014-12-18T16:27:06+00:00","author":{"name":"inma s","image":"https:\/\/pbs.twimg.com\/profile_images\/474961002379747328\/O7E3Xcvh_normal.jpeg","description":"Aprendiendo sobre el asma alergica. Ecologista.","id_on_source":"s_inma","tweeter_id":"300771446","geo":{"lt":null,"ln":null},"followers":411},"tweet_id":"545616254808387584"},{"url":"https:\/\/twitter.com\/AsthmaTuz\/status\/545627066872627200","license":"datasift","citation_ids":[2996219],"posted_on":"2014-12-18T17:10:04+00:00","author":{"name":"#Asthma","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000435276798\/1e45378c76e9cab0940585a4f1291885_normal.jpeg","description":"Latest news about #asthma.","id_on_source":"AsthmaTuz","tweeter_id":"1561143752","followers":298},"tweet_id":"545627066872627200"},{"url":"https:\/\/twitter.com\/asthma_papers\/status\/546985151243108352","license":"datasift","citation_ids":[2996219],"posted_on":"2014-12-22T11:06:37+00:00","author":{"name":"Asthma Papers","url":"https:\/\/github.com\/roblanf\/phypapers","image":"https:\/\/pbs.twimg.com\/profile_images\/439482171208646656\/OWe4b0kE_normal.jpeg","description":"RSS feed for #asthma papers in #Pubmed. Create a feed of your own using instructions here:","id_on_source":"asthma_papers","tweeter_id":"2366030767","geo":{"lt":null,"ln":null},"followers":565},"tweet_id":"546985151243108352"},{"url":"https:\/\/twitter.com\/jvalverde64\/status\/547492462588358656","license":"datasift","rt":["Aller_MD"],"citation_ids":[2996219],"posted_on":"2014-12-23T20:42:29+00:00","author":{"name":"Jos\u00e9 Valverde-Molina","url":"https:\/\/www.researchgate.net\/profile\/Jose_Valverde-Molina2","image":"https:\/\/pbs.twimg.com\/profile_images\/688447568813146122\/irDhuNWn_normal.jpg","description":"Pediatra Neum\u00f3logo. Jefe de Secci\u00f3n de Pediatr\u00eda. Hospital Universitario los Arcos del Mar Menor.\nPresidente de la SPSE","id_on_source":"jvalverde64","tweeter_id":"1055305087","geo":{"lt":38,"ln":-1.5,"country":"ES"},"followers":709},"tweet_id":"547492462588358656"},{"url":"https:\/\/twitter.com\/Allergy\/status\/547521540418719747","license":"datasift","citation_ids":[2996219],"posted_on":"2014-12-23T22:38:02+00:00","author":{"name":"Ves Dimov, M.D.","url":"http:\/\/allergynotes.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/292966342\/AB1_normal.png","description":"Allergist\/Immunologist at Cleveland Clinic. Associate Professor at FAU http:\/\/AllergyGoAway.com. World Allergy Organization WAO TV Editor. See disclaimer","id_on_source":"Allergy","tweeter_id":"20159122","geo":{"lt":26.12231,"ln":-80.14338,"country":"US"},"followers":4454},"tweet_id":"547521540418719747"},{"url":"https:\/\/twitter.com\/asthma_papers\/status\/589081912389414913","license":"datasift","citation_ids":[2996219],"posted_on":"2015-04-17T15:04:07+00:00","author":{"name":"Asthma Papers","url":"https:\/\/github.com\/roblanf\/phypapers","image":"https:\/\/pbs.twimg.com\/profile_images\/439482171208646656\/OWe4b0kE_normal.jpeg","description":"RSS feed for #asthma papers in #Pubmed. Create a feed of your own using instructions here:","id_on_source":"asthma_papers","tweeter_id":"2366030767","geo":{"lt":null,"ln":null},"followers":565},"tweet_id":"589081912389414913"}],"googleplus":[{"title":"Omalizumab therapy for #asthma patients with poor adherence to inhaled corticosteroid therapy","url":"https:\/\/plus.google.com\/103955470514107667760\/posts\/YKebTsTU7Nk","citation_ids":[2996219],"posted_on":"2014-12-18T17:00:21+00:00","summary":"Omalizumab therapy for #asthma patients with poor adherence to inhaled corticosteroid therapy Omalizumab therapy for #asthma patients with poor adherence to inhaled corticosteroid therapy\ufeff Omalizumab therapy for asthma patients with poor adherence to inhal","author":{"name":"Consultorio de Alergia, Asma e Inmunolog\u00eda - Dr. Juan Carlos Ivancevich","url":"https:\/\/plus.google.com\/103955470514107667760","image":"https:\/\/lh6.googleusercontent.com\/-gkpEvOu1tag\/AAAAAAAAAAI\/AAAAAAAAAA8\/EIzkCYHzZDw\/photo.jpg?sz=50","id_on_source":"103955470514107667760"}}],"facebook":[{"title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy - Annals of Allergy, Asthma & Immunology","url":"https:\/\/www.facebook.com\/100000445602493\/posts\/843331889062549","license":"public","citation_ids":[2996219],"posted_on":"2014-12-19T14:10:37+00:00","summary":"www.annallergy.org","author":{"name":"Juan C. Ivancevich","url":"https:\/\/www.facebook.com\/100000445602493","facebook_wall_name":"Juan C. Ivancevich","image":"https:\/\/graph.facebook.com\/100000445602493\/picture","id_on_source":"100000445602493"}},{"title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy - Annals of Allergy, Asthma & Immunology","url":"https:\/\/www.facebook.com\/100001970301308\/posts\/763497463725923","license":"public","citation_ids":[2996219],"posted_on":"2014-12-20T10:48:11+00:00","summary":"www.annallergy.org","author":{"name":"Surgeon ON Call","url":"https:\/\/www.facebook.com\/100001970301308","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/100001970301308\/picture","id_on_source":"100001970301308"}},{"title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy - Annals of Allergy, Asthma & Immunology","url":"https:\/\/www.facebook.com\/579254068\/posts\/10152654643174069","license":"public","citation_ids":[2996219],"posted_on":"2014-12-21T03:03:58+00:00","summary":"www.annallergy.org","author":{"name":"Ana Fassrainer","url":"https:\/\/www.facebook.com\/579254068","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/579254068\/picture","id_on_source":"579254068"}},{"title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy - Annals of Allergy, Asthma & Immunology","url":"https:\/\/www.facebook.com\/579254068\/posts\/10152654643109069","license":"public","citation_ids":[2996219],"posted_on":"2014-12-21T03:03:56+00:00","summary":"www.annallergy.org","author":{"name":"Ana Fassrainer","url":"https:\/\/www.facebook.com\/579254068","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/579254068\/picture","id_on_source":"579254068"}},{"title":"Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy - Annals of Allergy, Asthma & Immunology","url":"https:\/\/www.facebook.com\/1653562713\/posts\/10204856763012884","license":"public","citation_ids":[2996219],"posted_on":"2014-12-27T20:07:35+00:00","summary":"www.annallergy.org","author":{"name":"Antonio Pinto","url":"https:\/\/www.facebook.com\/1653562713","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/1653562713\/picture","id_on_source":"1653562713"}}],"news":[{"title":"Einfluss der Pharmaindustrie: \"Kann man das nicht abschw\u00e4chen?\"","url":"http:\/\/www.sueddeutsche.de\/gesundheit\/medizin-kann-man-das-nicht-abschwaechen-1.2419538","license":"public","citation_ids":[2996219],"posted_on":"2015-04-06T16:47:00+00:00","summary":"Weil ein kritisches Editorial entsch\u00e4rft werden soll, tritt der Herausgeber eines \u00c4rztejournals zur\u00fcck. Die Pharmaindustrie hat zu viel Einfluss auf Fachzeitschriften.","author":{"name":"S\u00fcddeutsche.de","url":"http:\/\/www.sueddeutsche.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/011\/normal\/image.png?1369859940"}}]}}